Sodium diphenyl hydantoinate has been used at the neurologic clinic of the Boston City Hospital for the past two years. During this time we have administered the drug to more than 350 patients. A detailed report of the therapeutic results in 142 of these patients has been previously made,1 and the statistics on the entire series up to date are now in the press. It is the purpose of this communication to give our opinion regarding the regulation of the dose and the treatment and prevention of toxic reactions.
In an attempt to evaluate the therapeutic efficiency of sodium diphenyl hydantoinate, it was thought advisable to use the drug only with patients who had received other forms of therapy, such as phenobarbital, bromides, a ketogenic diet, low fluid intake and surgical procedures and had not been relieved of their attacks. For the vast majority of our patients phenobarbital, sometimes
MERRITT HH, PUTNAM TJ. SODIUM DIPHENYL HYDANTOINATE IN TREATMENT OF CONVULSIVE SEIZURESTOXIC SYMPTOMS AND THEIR PREVENTION. Arch NeurPsych. 1939;42(6):1053–1058. doi:10.1001/archneurpsyc.1939.02270240091005